Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability

Summary

The Food and Drug Administration (FDA) has released a final guidance for industry on compounding certain ibuprofen oral suspension products under Section 503B of the Federal Food, Drug, and Cosmetic Act, outlining the agency's priorities for regulating these products in outsourcing facilities for hospital administration.